{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:32:00Z","timestamp":1781058720190,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["019201"],"award-info":[{"award-number":["019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["019201"],"award-info":[{"award-number":["019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["019201"],"award-info":[{"award-number":["019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disease, for which no disease-modifying therapies exist. Preclinical and clinical evidence suggest that hypoxia-based therapy might have short- and long-term benefits in PD. We present the contours of the first study to assess the safety, feasibility and physiological and symptomatic impact of hypoxia-based therapy in individuals with PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Design<\/jats:title>\n                <jats:p>In 20 individuals with PD, we will investigate the safety, tolerability and short-term symptomatic efficacy of continuous and intermittent hypoxia using individual, double-blind, randomized placebo-controlled N-of-1 trials. This design allows for dose finding and for including more individualized outcomes, as each individual serves as its own control. A wide range of exploratory outcomes is deployed, including the Movement Disorders Society Unified Parkinson\u2019s Disease Rating scale (MDS-UPDRS) part III, Timed Up &amp; Go Test, Mini Balance Evaluation Systems (MiniBES) test and wrist accelerometry. Also, self-reported impression of overall symptoms, motor and non-motor symptoms and urge to take dopaminergic medication will be assessed on a 10-point Likert scale. As part of a hypothesis-generating part of the study, we also deploy several exploratory outcomes to probe possible underlying mechanisms of action, including cortisol, erythropoietin and platelet-derived growth factor \u03b2. Efficacy will be assessed primarily by a Bayesian analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This evaluation of hypoxia therapy could provide insight in novel pathways that may be pursued for PD treatment. This trial also serves as a proof of concept for deploying an N-of-1 design and for including individualized outcomes in PD research, as a basis for personalized treatment approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT05214287 (registered January 28, 2022).\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02770-7","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:03:47Z","timestamp":1657796627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson\u2019s disease: study rationale and protocol"],"prefix":"10.1186","volume":"22","author":[{"given":"Jules M.","family":"Janssen Daalen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan J.","family":"Meinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit C. B.","family":"Roes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas C.","family":"Stunnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soania","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Ainslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick H. J.","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"issue":"1","key":"2770_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75(1):9\u201310.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2770_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1152\/physrev.00030.2011","volume":"92","author":"NR Prabhakar","year":"2012","unstructured":"Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev. 2012;92(3):967\u20131003.","journal-title":"Physiol Rev"},{"key":"2770_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-physiol-021113-170322","volume":"76","author":"GL Semenza","year":"2014","unstructured":"Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39\u201356.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"2770_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00999391","volume":"4","author":"PA Broderick","year":"1989","unstructured":"Broderick PA, Gibson GE. Dopamine and Serotonin in Rat Striatum during Invivo Hypoxic-Hypoxia. Metab Brain Dis. 1989;4(2):143\u201353.","journal-title":"Metab Brain Dis"},{"key":"2770_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3389\/fnins.2020.00869","volume":"14","author":"AS Barath","year":"2020","unstructured":"Barath AS, Rusheen AE, Rojas Cabrera JM, Price JB, Owen RL, Shin H, Jang DP, Blaha CD, Lee KH, Oh Y. Hypoxia-Associated Changes in Striatal Tonic Dopamine Release: Real-Time in vivo Measurements With a Novel Voltammetry Technique. Front Neurosci. 2020;14:869.","journal-title":"Front Neurosci"},{"issue":"8","key":"2770_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.neuint.2005.02.005","volume":"46","author":"C Orset","year":"2005","unstructured":"Orset C, Parrot S, Sauvinet V, Cottet-Emard JM, Berod A, Pequignot JM, Denoroy L. Dopamine transporters are involved in the onset of hypoxia-induced dopamine efflux in striatum as revealed by in vivo microdialysis. Neurochem Int. 2005;46(8):623\u201333.","journal-title":"Neurochem Int"},{"issue":"3","key":"2770_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1471-4159.1991.tb08249.x","volume":"57","author":"Y Akiyama","year":"1991","unstructured":"Akiyama Y, Koshimura K, Ohue T, Lee K, Miwa S, Yamagata S, Kikuchi H. Effects of hypoxia on the activity of the dopaminergic neuron system in the rat striatum as studied by in vivo brain microdialysis. J Neurochem. 1991;57(3):997\u20131002.","journal-title":"J Neurochem"},{"issue":"7","key":"2770_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/jnr.21988","volume":"87","author":"L Witten","year":"2009","unstructured":"Witten L, Sager T, Thirstrup K, Johansen JL, Larsen DB, Montezinho LP, M\u00f8rk A. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J Neurosci Res. 2009;87(7):1686\u201394.","journal-title":"J Neurosci Res"},{"issue":"1","key":"2770_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1471-4159.2010.06917.x","volume":"115","author":"JL Johansen","year":"2010","unstructured":"Johansen JL, Sager TN, Lotharius J, Witten L, M\u00f8rk A, Egebjerg J, Thirstrup K. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J Neurochem. 2010;115(1):209\u201319.","journal-title":"J Neurochem"},{"issue":"6","key":"2770_CR10","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1074\/jbc.M407706200","volume":"280","author":"G Yuan","year":"2005","unstructured":"Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+\/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem. 2005;280(6):4321\u20138.","journal-title":"J Biol Chem"},{"key":"2770_CR11","doi-asserted-by":"crossref","unstructured":"Belikova MV, Kolesnikova EE, Serebrovskaya TV: Intermittent hypoxia and experimental Parkinson's disease. In: Intermittent hypoxia and human diseases. edn. Edited by Xi L, Serebrovskaya T. London: Springer; 2012: 147\u2013153.","DOI":"10.1007\/978-1-4471-2906-6_12"},{"issue":"3","key":"2770_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1365-201X.1998.00335.x","volume":"162","author":"M Rostrup","year":"1998","unstructured":"Rostrup M. Catecholamines, hypoxia and high altitude. Acta Physiol Scand. 1998;162(3):389\u201399.","journal-title":"Acta Physiol Scand"},{"issue":"2","key":"2770_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1471-4159.2003.01696.x","volume":"85","author":"PO Schnell","year":"2003","unstructured":"Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, Czyzyk-Krzeska MF. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem. 2003;85(2):483\u201391.","journal-title":"J Neurochem"},{"issue":"6","key":"2770_CR14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1152\/jappl.1994.77.6.2537","volume":"77","author":"RL Hughson","year":"1994","unstructured":"Hughson RL, Yamamoto Y, McCullough RE, Sutton JR, Reeves JT. Sympathetic and parasympathetic indicators of heart rate control at altitude studied by spectral analysis. J Appl Physiol\u00a0 (1985). 1994;77(6):2537\u201342.","journal-title":"J Appl Physiol\u00a0 (1985)"},{"issue":"Pt 3","key":"2770_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1113\/jphysiol.2002.031765","volume":"546","author":"J Hansen","year":"2003","unstructured":"Hansen J, Sander M. Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol. 2003;546(Pt 3):921\u20139.","journal-title":"J Physiol"},{"issue":"4","key":"2770_CR16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1152\/jappl.1989.66.4.1736","volume":"66","author":"LB Rowell","year":"1989","unstructured":"Rowell LB, Johnson DG, Chase PB, Comess KA, Seals DR. Hypoxemia raises muscle sympathetic activity but not norepinephrine in resting humans. J Appl Physiol\u00a0 (1985). 1989;66(4):1736\u201343.","journal-title":"J Appl Physiol\u00a0 (1985)"},{"issue":"14","key":"2770_CR17","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov Disord. 2014;29(14):1710\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"2770_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/mds.28544","volume":"36","author":"J Burtscher","year":"2021","unstructured":"Burtscher J, Syed MMK, Lashuel HA, Millet GP. Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson\u2019s Disease? Mov Disord. 2021;36(4):857\u201361.","journal-title":"Mov Disord"},{"issue":"28","key":"2770_CR19","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2174\/092986711797200426","volume":"18","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Yan J, Chang Y, Yan SSD, Shi H. Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases. Curr Med Chem. 2011;18(28):4335\u201343.","journal-title":"Curr Med Chem"},{"issue":"6281","key":"2770_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.aad9642","volume":"352","author":"IH Jain","year":"2016","unstructured":"Jain IH, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger O, Peng J, Shalem O, Sanjana NE, et al. Hypoxia as a therapy for mitochondrial disease. Science. 2016;352(6281):54\u201361.","journal-title":"Science"},{"key":"2770_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113891","volume":"347","author":"AK Vose","year":"2022","unstructured":"Vose AK, Welch JF, Nair J, Dale EA, Fox EJ, Muir GD, Trumbower RD, Mitchell GS. Therapeutic acute intermittent hypoxia: A translational roadmap for spinal cord injury and neuromuscular disease. Exp Neurol. 2022;347: 113891.","journal-title":"Exp Neurol"},{"issue":"21","key":"2770_CR22","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.3390\/ijms20215405","volume":"20","author":"ZO Serebrovska","year":"2019","unstructured":"Serebrovska ZO, Serebrovska TV, Kholin VA, Tumanovska LV, Shysh AM, Pashevin DA, Goncharov SV, Stroy D, Grib ON, Shatylo VB, et al. Intermittent Hypoxia-Hyperoxia Training Improves Cognitive Function and Decreases Circulating Biomarkers of Alzheimer\u2019s Disease in Patients with Mild Cognitive Impairment: A Pilot Study. Int J Mol Sci. 2019;20(21):5405.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2770_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2012.02.003","volume":"18","author":"O Saeed","year":"2012","unstructured":"Saeed O, Bhatia V, Formica P, Browne A, Aldrich TK, Shin JJ, Maybaum S. Improved exercise performance and skeletal muscle strength after simulated altitude exposure: a novel approach for patients with chronic heart failure. J Card Fail. 2012;18(5):387\u201391.","journal-title":"J Card Fail"},{"issue":"2","key":"2770_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2003.07.021","volume":"96","author":"M Burtscher","year":"2004","unstructured":"Burtscher M, Pachinger O, Ehrenbourg I, Mitterbauer G, Faulhaber M, Puhringer R, Tkatchouk E. Intermittent hypoxia increases exercise tolerance in elderly men with and without coronary artery disease. Int J Cardiol. 2004;96(2):247\u201354.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2770_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.resp.2008.10.012","volume":"165","author":"M Burtscher","year":"2009","unstructured":"Burtscher M, Haider T, Domej W, Linser T, Gatterer H, Faulhaber M, Pocecco E, Ehrenburg I, Tkatchuk E, Koch R, et al. Intermittent hypoxia increases exercise tolerance in patients at risk for or with mild COPD. Respir Physiol Neurobiol. 2009;165(1):97\u2013103.","journal-title":"Respir Physiol Neurobiol"},{"issue":"1","key":"2770_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.trci.2017.01.002","volume":"3","author":"U Bayer","year":"2017","unstructured":"Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B, Neuwersch S, Glazachev O, Burtscher M. Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimers Dement (N Y). 2017;3(1):114\u201322.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"2770_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00007256-200939020-00002","volume":"39","author":"DL Bonetti","year":"2009","unstructured":"Bonetti DL, Hopkins WG. Sea-level exercise performance following adaptation to hypoxia: a meta-analysis. Sports Med. 2009;39(2):107\u201327.","journal-title":"Sports Med"},{"issue":"3","key":"2770_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000029507","volume":"67","author":"TV Serebrovskaya","year":"2000","unstructured":"Serebrovskaya TV, Karaban IN, Kolesnikova EE, Mishunina TM, Swanson RJ, Beloshitsky PV, Ilyin VN, Krasuk AN, Safronova OS, Kuzminskaya LA. Geriatric men at altitude: hypoxic ventilatory sensitivity and blood dopamine changes. Respiration. 2000;67(3):253\u201360.","journal-title":"Respiration"},{"issue":"1","key":"2770_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12877-019-1184-1","volume":"19","author":"U Bayer","year":"2019","unstructured":"Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B, Neuwersch S, Glazachev O, Burtscher M. Effects of intermittent hypoxia-hyperoxia on mobility and perceived health in geriatric patients performing a multimodal training intervention: a randomized controlled trial. BMC Geriatr. 2019;19(1):167.","journal-title":"BMC Geriatr"},{"key":"2770_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113483","volume":"335","author":"L Christiansen","year":"2021","unstructured":"Christiansen L, Chen B, Lei Y, Urbin MA, Richardson MSA, Oudega M, Sandhu M, Rymer WZ, Trumbower RD, Mitchell GS, et al. Acute intermittent hypoxia boosts spinal plasticity in humans with tetraplegia. Exp Neurol. 2021;335: 113483.","journal-title":"Exp Neurol"},{"issue":"2","key":"2770_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","volume":"8","author":"EO Lillie","year":"2011","unstructured":"Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011;8(2):161\u201373.","journal-title":"Per Med"},{"issue":"22","key":"2770_CR32","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1001\/jama.2018.18020","volume":"320","author":"BC Stunnenberg","year":"2018","unstructured":"Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, Stegeman DF, Timmermans J, Trivedi J, Matthews E, et al. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA. 2018;320(22):2344\u201353.","journal-title":"JAMA"},{"issue":"4","key":"2770_CR33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1017\/S0266462314000464","volume":"30","author":"K Facey","year":"2014","unstructured":"Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt GJ, Wong-Rieger D. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416\u201322.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"2770_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1472-8206.2011.00951.x","volume":"26","author":"O Rascol","year":"2012","unstructured":"Rascol O, Ferreira J, N\u00e8gre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemari\u00e9 JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson\u2019s disease. Fundam Clin Pharmacol. 2012;26(4):557\u201364.","journal-title":"Fundam Clin Pharmacol"},{"key":"2770_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fneur.2016.00027","volume":"7","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O. Espresso Coffee for the Treatment of Somnolence in Parkinson\u2019s Disease: Results of n-of-1 Trials. Front Neurol. 2016;7:27.","journal-title":"Front Neurol"},{"issue":"4","key":"2770_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/healthcare7040137","volume":"7","author":"JW Blackston","year":"2019","unstructured":"Blackston JW, Chapple AG, McGree JM, McDonald S, Nikles J. Comparison of Aggregated N-of-1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies. Healthcare (Basel). 2019;7(4):137.","journal-title":"Healthcare (Basel)"},{"key":"2770_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2288-13-104","volume":"13","author":"SA Billingham","year":"2013","unstructured":"Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013;13:104.","journal-title":"BMC Med Res Methodol"},{"key":"2770_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.570472","volume":"11","author":"J Soo","year":"2020","unstructured":"Soo J, Girard O, Ihsan M, Fairchild T. The Use of the SpO2 to FiO2 Ratio to Individualize the Hypoxic Dose in Sport Science, Exercise, and Health Settings. Front Physiol. 2020;11: 570472.","journal-title":"Front Physiol"},{"issue":"10","key":"2770_CR39","doi-asserted-by":"publisher","first-page":"R1181","DOI":"10.1152\/ajpregu.00208.2014","volume":"307","author":"A Navarrete-Opazo","year":"2014","unstructured":"Navarrete-Opazo A, Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. Am J Physiol Regul Integr Comp Physiol. 2014;307(10):R1181-1197.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"2770_CR40","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1152\/japplphysiol.00564.2014","volume":"118","author":"JH Mateika","year":"2015","unstructured":"Mateika JH, El-Chami M, Shaheen D, Ivers B. Intermittent hypoxia: a low-risk research tool with therapeutic value in humans. J Appl Physiol\u00a0 (1985). 2015;118(5):520\u201332.","journal-title":"J Appl Physiol\u00a0 (1985)"},{"issue":"3","key":"2770_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.15407\/fz62.03.078","volume":"62","author":"TV Serebrovska","year":"2016","unstructured":"Serebrovska TV, Serebrovska ZO, Egorov E. Fitness and therapeutic potential of intermittent hypoxia training: a matter of dose. Fiziol Zh. 2016;62(3):78\u201391.","journal-title":"Fiziol Zh"},{"issue":"3","key":"2770_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1580\/1080-6032(2000)011[0172:IVCHEO]2.3.CO;2","volume":"11","author":"N Garcia","year":"2000","unstructured":"Garcia N, Hopkins SR, Powell FL. Intermittent vs continuous hypoxia: effects on ventilation and erythropoiesis in humans. Wilderness Environ Med. 2000;11(3):172\u20139.","journal-title":"Wilderness Environ Med"},{"issue":"Pt 1","key":"2770_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1469-7793.2000.00215.x","volume":"529","author":"TL Baker","year":"2000","unstructured":"Baker TL, Mitchell GS. Episodic but not continuous hypoxia elicits long-term facilitation of phrenic motor output in rats. J Physiol. 2000;529(Pt 1):215\u20139.","journal-title":"J Physiol"},{"issue":"3","key":"2770_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10557-010-6237-9","volume":"24","author":"DJ Hausenloy","year":"2010","unstructured":"Hausenloy DJ, Yellon DM. The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther. 2010;24(3):235\u201354.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2770_CR45","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/982934","volume":"2012","author":"CA Grande","year":"2012","unstructured":"Grande CA. Advances in Pressure Swing Adsorption for Gas Separation. ISRN Chemical Engineering. 2012;2012: 982934.","journal-title":"ISRN Chemical Engineering"},{"issue":"6","key":"2770_CR46","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1152\/japplphysiol.00647.2017","volume":"123","author":"X Liu","year":"2017","unstructured":"Liu X, Xu D, Hall JR, Ross S, Chen S, Liu H, Mallet RT, Shi X. Enhanced cerebral perfusion during brief exposures to cyclic intermittent hypoxemia. J Appl Physiol\u00a0 (1985). 2017;123(6):1689\u201397.","journal-title":"J Appl Physiol\u00a0 (1985)"},{"issue":"3","key":"2770_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0034-5687(97)02523-1","volume":"107","author":"JA Loeppky","year":"1997","unstructured":"Loeppky JA, Icenogle M, Scotto P, Robergs R, Hinghofer-Szalkay H, Roach RC. Ventilation during simulated altitude, normobaric hypoxia and normoxic hypobaria. Respir Physiol. 1997;107(3):231\u20139.","journal-title":"Respir Physiol"},{"key":"2770_CR48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0928-4680(98)81208-X","volume":"5","author":"T Serebrovskaya","year":"1998","unstructured":"Serebrovskaya T, Kolesnikova E, Karaban I, Mishunina T, Mankovskaya I, Safronova O. Intermittent hypoxia (IH) improves hypoxic ventilatory sensitivity and blood dopamine (DA) in patients with Parkinson\u2019s disease (PD). Pathophysiology. 1998;5:234\u2013234.","journal-title":"Pathophysiology"},{"issue":"5","key":"2770_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, Bakken S, Kaplan CP, Squiers L, Fabrizio C, et al. How we design feasibility studies. Am J Prev Med. 2009;36(5):452\u20137.","journal-title":"Am J Prev Med"},{"key":"2770_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1738","volume":"350","author":"S Vohra","year":"2015","unstructured":"Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ. 2015;350: h1738.","journal-title":"BMJ"},{"key":"2770_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m122","volume":"368","author":"AJ Porcino","year":"2020","unstructured":"Porcino AJ, Shamseer L, Chan AW, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ. 2020;368: m122.","journal-title":"BMJ"},{"issue":"3","key":"2770_CR52","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/h0061266","volume":"32","author":"J Tiffin","year":"1948","unstructured":"Tiffin J, Asher EJ. The Purdue Pegboard: norms and studies of reliability and validity. J Appl Psychol. 1948;32(3):234\u201347.","journal-title":"J Appl Psychol"},{"issue":"2","key":"2770_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S. The timed \u201cUp & Go\u201d: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2770_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2340\/16501977-0537","volume":"42","author":"F Franchignoni","year":"2010","unstructured":"Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the Balance Evaluation System\u2019s Test: the mini-BESTest. Journal of rehabilitation medicine: official journal of the UEMS European Board of Physical and Rehabilitation Medicine. 2010;42(4):323.","journal-title":"Journal of rehabilitation medicine: official journal of the UEMS European Board of Physical and Rehabilitation Medicine"},{"key":"2770_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113722","volume":"342","author":"MS Sandhu","year":"2021","unstructured":"Sandhu MS, Perez MA, Oudega M, Mitchell GS, Rymer WZ. Efficacy and time course of acute intermittent hypoxia effects in the upper extremities of people with cervical spinal cord injury. Exp Neurol. 2021;342: 113722.","journal-title":"Exp Neurol"},{"issue":"14","key":"2770_CR56","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198604033141406","volume":"314","author":"G Guyatt","year":"1986","unstructured":"Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy\u2013randomized trials in individual patients. N Engl J Med. 1986;314(14):889\u201392.","journal-title":"N Engl J Med"},{"issue":"5","key":"2770_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26(5):353\u20137.","journal-title":"Age Ageing"},{"issue":"1","key":"2770_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1479-5868-8-115","volume":"8","author":"PH Lee","year":"2011","unstructured":"Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the international physical activity questionnaire short form (IPAQ-SF): A systematic review. Int J Behav Nutr Phys Act. 2011;8(1):115.","journal-title":"Int J Behav Nutr Phys Act"},{"key":"2770_CR59","doi-asserted-by":"crossref","unstructured":"Zhang SXL, Gozal D, Sachleben LR, Rane M, Klein JB, Gozal E: Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B\/PDGF-beta receptor\/phosphatidylinositol 3-kinase\/Akt signaling in RN46A neuronal cells. Faseb J 2003, 17(10):1709-+.","DOI":"10.1096\/fj.02-1111fje"},{"issue":"1","key":"2770_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-020-01051-z","volume":"8","author":"SK Halder","year":"2020","unstructured":"Halder SK, Milner R. Mild hypoxia triggers transient blood-brain barrier disruption: a fundamental protective role for microglia. Acta Neuropathol Commun. 2020;8(1):175.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2770_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.mvr.2012.05.008","volume":"84","author":"A Al Ahmad","year":"2012","unstructured":"Al Ahmad A, Gassmann M, Ogunshola OO. Involvement of oxidative stress in hypoxia-induced blood-brain barrier breakdown. Microvasc Res. 2012;84(2):222\u20135.","journal-title":"Microvasc Res"},{"issue":"3","key":"2770_CR62","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1254\/jphs.09102FP","volume":"110","author":"S Tsunekawa","year":"2009","unstructured":"Tsunekawa S, Ohi Y, Ishii Y, Sasahara M, Haji A. Hypoxic ventilatory response in platelet-derived growth factor receptor-beta-knockout mice. J Pharmacol Sci. 2009;110(3):270\u20135.","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"2770_CR63","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1177\/0271678X18769515","volume":"39","author":"J Shen","year":"2019","unstructured":"Shen J, Xu G, Zhu R, Yuan J, Ishii Y, Hamashima T, Matsushima T, Yamamoto S, Takatsuru Y, Nabekura J, et al. PDGFR-beta restores blood-brain barrier functions in a mouse model of focal cerebral ischemia. J Cereb Blood Flow Metab. 2019;39(8):1501\u201315.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2770_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neulet.2015.09.025","volume":"607","author":"AP Sagare","year":"2015","unstructured":"Sagare AP, Sweeney MD, Makshanoff J, Zlokovic BV. Shedding of soluble platelet-derived growth factor receptor-beta from human brain pericytes. Neurosci Lett. 2015;607:97\u2013101.","journal-title":"Neurosci Lett"},{"issue":"1","key":"2770_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0271678X17719645","volume":"38","author":"A Gaceb","year":"2018","unstructured":"Gaceb A, Ozen I, Padel T, Barbariga M, Paul G. Pericytes secrete pro-regenerative molecules in response to platelet-derived growth factor-BB. J Cereb Blood Flow Metab. 2018;38(1):45\u201357.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2770_CR66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nbd.2016.06.002","volume":"94","author":"T Padel","year":"2016","unstructured":"Padel T, Ozen I, Boix J, Barbariga M, Gaceb A, Roth M, Paul G. Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson\u2019s disease. Neurobiol Dis. 2016;94:95\u2013105.","journal-title":"Neurobiol Dis"},{"key":"2770_CR67","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.steroids.2005.05.003","volume":"70","author":"O Coste","year":"2005","unstructured":"Coste O, Beers P, Bogdan A, Charbuy H, Touitou Y. Hypoxic alteration of cortisol circadian rhythm in man after simulation of a long duration flight. Steroids. 2005;70:803\u201310.","journal-title":"Steroids"},{"key":"2770_CR68","doi-asserted-by":"publisher","first-page":"175909141987142","DOI":"10.1177\/1759091419871420","volume":"11","author":"F Rey","year":"2019","unstructured":"Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M, Carelli S. Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases. ASN Neuro. 2019;11:1759091419871420.","journal-title":"ASN Neuro"},{"issue":"2","key":"2770_CR69","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1471-4159.2005.03587.x","volume":"96","author":"AP Signore","year":"2006","unstructured":"Signore AP, Weng Z, Hastings T, Van Laar AD, Liang Q, Lee YJ, Chen J. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem. 2006;96(2):428\u201343.","journal-title":"J Neurochem"},{"issue":"6","key":"2770_CR70","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1007\/s12035-015-9316-x","volume":"53","author":"W Jang","year":"2016","unstructured":"Jang W, Kim HJ, Li H, Jo KD, Lee MK, Yang HO. The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy. Mol Neurobiol. 2016;53(6):3812\u201321.","journal-title":"Mol Neurobiol"},{"issue":"22","key":"2770_CR71","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1001\/jama.2018.17977","volume":"320","author":"AE McGlothlin","year":"2018","unstructured":"McGlothlin AE, Viele K. Bayesian Hierarchical Models. JAMA. 2018;320(22):2365\u20136.","journal-title":"JAMA"},{"key":"2770_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12883-015-0294-4","volume":"15","author":"BC Stunnenberg","year":"2015","unstructured":"Stunnenberg BC, Woertman W, Raaphorst J, Statland JM, Griggs RC, Timmermans J, Saris CG, Schouwenberg BJ, Groenewoud HM, Stegeman DF, et al. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurol. 2015;15:43.","journal-title":"BMC Neurol"},{"key":"2770_CR73","unstructured":"Kravitz R, Duan N, Eslick I, Gabler N, Kaplan H, Larson E: Design and implementation of N-of-1 trials: a user\u2019s guide. Agency for healthcare research and quality, US Department of Health and Human Services 2014."},{"key":"2770_CR74","unstructured":"Plummer M: JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In."},{"key":"2770_CR75","unstructured":"Team RC: R: A language and environment for statistical computing. 2013."},{"key":"2770_CR76","unstructured":"Plummer M, Stukalov A, Denwood M, Plummer MM: Package \u2018rjags\u2019. update 2019, 1."},{"key":"2770_CR77","doi-asserted-by":"crossref","unstructured":"Christiansen L, Urbin MA, Mitchell GS, Perez MA: Acute intermittent hypoxia enhances corticospinal synaptic plasticity in humans. Elife 2018, 7.","DOI":"10.7554\/eLife.34304"},{"issue":"2","key":"2770_CR78","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1212\/01.WNL.0000437416.34298.43","volume":"82","author":"HB Hayes","year":"2014","unstructured":"Hayes HB, Jayaraman A, Herrmann M, Mitchell GS, Rymer WZ, Trumbower RD. Daily intermittent hypoxia enhances walking after chronic spinal cord injury: a randomized trial. Neurology. 2014;82(2):104\u201313.","journal-title":"Neurology"},{"issue":"18","key":"2770_CR79","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1212\/WNL.0000000000004596","volume":"89","author":"RD Trumbower","year":"2017","unstructured":"Trumbower RD, Hayes HB, Mitchell GS, Wolf SL, Stahl VA. Effects of acute intermittent hypoxia on hand use after spinal cord trauma: A preliminary study. Neurology. 2017;89(18):1904\u20137.","journal-title":"Neurology"},{"issue":"2","key":"2770_CR80","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1545968311412055","volume":"26","author":"RD Trumbower","year":"2012","unstructured":"Trumbower RD, Jayaraman A, Mitchell GS, Rymer WZ. Exposure to acute intermittent hypoxia augments somatic motor function in humans with incomplete spinal cord injury. Neurorehabil Neural Repair. 2012;26(2):163\u201372.","journal-title":"Neurorehabil Neural Repair"},{"key":"2770_CR81","doi-asserted-by":"crossref","unstructured":"Vivodtzev I, Tan AQ, Hermann M, Jayaraman A, Stahl V, Rymer WZ, Mitchell GS, Hayes HB, Trumbower RD: Mild to moderate sleep apnea is linked to hypoxia-induced motor recovery after spinal cord injury. Am J Respir Crit Care Med 2020.","DOI":"10.1164\/rccm.202002-0245LE"},{"issue":"12","key":"2770_CR82","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.2337\/db13-0167","volume":"62","author":"T Duennwald","year":"2013","unstructured":"Duennwald T, Bernardi L, Gordin D, Sandelin A, Syreeni A, Fogarty C, Kyto JP, Gatterer H, Lehto M, Horkko S, et al. Effects of a single bout of interval hypoxia on cardiorespiratory control in patients with type 1 diabetes. Diabetes. 2013;62(12):4220\u20137.","journal-title":"Diabetes"},{"issue":"8","key":"2770_CR83","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2337\/dc12-2113","volume":"36","author":"T Duennwald","year":"2013","unstructured":"Duennwald T, Gatterer H, Groop PH, Burtscher M, Bernardi L. Effects of a single bout of interval hypoxia on cardiorespiratory control and blood glucose in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2183\u20139.","journal-title":"Diabetes Care"},{"issue":"5","key":"2770_CR84","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/02640410903581588","volume":"28","author":"M Faulhaber","year":"2010","unstructured":"Faulhaber M, Gatterer H, Haider T, Patterson C, Burtscher M. Intermittent hypoxia does not affect endurance performance at moderate altitude in well-trained athletes. J Sports Sci. 2010;28(5):513\u20139.","journal-title":"J Sports Sci"},{"key":"2770_CR85","doi-asserted-by":"crossref","unstructured":"Gatterer H, Menz V, Burtscher M: Acute Moderate Hypoxia Reduces One-Legged Cycling Performance Despite Compensatory Increase in Peak Cardiac Output: A Pilot Study. Int J Environ Res Public Health 2021, 18(7).","DOI":"10.3390\/ijerph18073732"},{"issue":"2","key":"2770_CR86","first-page":"255","volume":"30","author":"U Bayer","year":"2017","unstructured":"Bayer U, Glazachev OS, Likar R, Burtscher M, Kofler W, Pinter G, Stettner H, Demschar S, Trummer B, Neuwersch S. Adaptation to intermittent hypoxia-hyperoxia improves cognitive performance and exercise tolerance in elderly. Adv Gerontol. 2017;30(2):255\u201361.","journal-title":"Adv Gerontol"},{"issue":"3","key":"2770_CR87","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000431157","volume":"8","author":"H Gatterer","year":"2015","unstructured":"Gatterer H, Haacke S, Burtscher M, Faulhaber M, Melmer A, Ebenbichler C, Strohl KP, Hogel J, Netzer NC. Normobaric Intermittent Hypoxia over 8 Months Does Not Reduce Body Weight and Metabolic Risk Factors\u2013a Randomized, Single Blind, Placebo-Controlled Study in Normobaric Hypoxia and Normobaric Sham Hypoxia. Obes Facts. 2015;8(3):200\u20139.","journal-title":"Obes Facts"},{"issue":"5","key":"2770_CR88","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/j.1600-0838.2012.01499.x","volume":"22","author":"M Wille","year":"2012","unstructured":"Wille M, Gatterer H, Mairer K, Philippe M, Schwarzenbacher H, Faulhaber M, Burtscher M. Short-term intermittent hypoxia reduces the severity of acute mountain sickness. Scand J Med Sci Sports. 2012;22(5):e79-85.","journal-title":"Scand J Med Sci Sports"},{"issue":"10","key":"2770_CR89","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/euhj.2000.2466","volume":"22","author":"L Bernardi","year":"2001","unstructured":"Bernardi L, Passino C, Serebrovskaya Z, Serebrovskaya T, Appenzeller O. Respiratory and cardiovascular adaptations to progressive hypoxia; effect of interval hypoxic training. Eur Heart J. 2001;22(10):879\u201386.","journal-title":"Eur Heart J"},{"issue":"4","key":"2770_CR90","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1183\/09031936.00156009","volume":"37","author":"JV Brugniaux","year":"2011","unstructured":"Brugniaux JV, Pialoux V, Foster GE, Duggan CT, Eliasziw M, Hanly PJ, Poulin MJ. Effects of intermittent hypoxia on erythropoietin, soluble erythropoietin receptor and ventilation in humans. Eur Respir J. 2011;37(4):880\u20137.","journal-title":"Eur Respir J"},{"key":"2770_CR91","volume-title":"Parkinson's disease and intermittent hypoxia training","author":"EE Kolesnikova","year":"2009","unstructured":"Kolesnikova EE, Serebrovskaya TV. Parkinson\u2019s disease and intermittent hypoxia training. Hauppauge: Nova Science Publishers, Inc; 2009."},{"issue":"4","key":"2770_CR92","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3233\/JPD-202223","volume":"10","author":"VA van de Wetering-van Dongen","year":"2020","unstructured":"van de Wetering-van Dongen VA, Kalf JG, van der Wees PJ, Bloem BR, Nijkrake MJ. The Effects of Respiratory Training in Parkinson\u2019s Disease: A Systematic Review. J Parkinsons Dis. 2020;10(4):1315\u201333.","journal-title":"J Parkinsons Dis"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02770-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:05:12Z","timestamp":1657803912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02770-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02770-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be performed according to the guidelines stated in the \u2018Declaration of Helsinki\u2019 from 2000 and \u2018the Medical Research Involving Human Subjects Act (WMO)\u2019 of the Civil Code of the Netherlands. This study has been reviewed and approved by the Medical Research Ethics Committee East Netherlands, The Netherlands, (reference number NL.77891.091.22) and has been registered at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05214287). Participants receive verbal and written information about the study by the coordinating investigator and written informed consent will be obtained before screening. Participants are covered by trial insurance issued specifically for this study by Radboud University Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bastiaan R. Bloem has received honoraria from serving on the scientific advisory board for Abbvie, Biogen, UCB, and Walk with Path; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial; and has received research support from The Netherlands Organisation for Scientific Research, the Michael J. Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, and the Parkinson Vereniging. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}